Endobronchial Valves

Description of Procedure or Service

Endobronchial valves are synthetic devices that are deployed with bronchoscopy into ventilatory airways of the lung for the purpose of controlling airflow. They have been investigated for use in patients who have prolonged broncho-pleural air leaks, as well as an alternative to lung volume reduction surgery (LVRS) in patients with lobar hyperinflation from severe emphysema.

Proper lung functioning is dependent upon a separation between the air-containing parts of the lung and the small vacuum-containing space around the lung called the pleural space. When air leaks into the pleural space the lung is unable to inflate resulting in hypoventilation and hypoxemia; this condition is known as a pneumothorax. A pneumothorax can result from a variety of processes including trauma, high airway pressures induced during mechanical ventilation, lung surgery, and rupture of lung blebs or bullae which may be congenital or a result of chronic obstructive pulmonary disease (COPD).

Although an air leak from the lung into the pleural space may seal spontaneously, it often requires intervention. Techniques currently employed to attempt air leak closure include the following:

- Inserting a chest tube (tube thoracostomy) and employing a water seal or one-way valve to evacuate air collected in the pleural space and prevent it from reaccumulating,
- Lowering airway pressures by adjusting the mechanical ventilator,
- Using autologous blood patches,
- Performing a thoracotomy with mechanical or chemical pleurodesis.

An endobronchial valve is a device that permits one-way air movement. During inhalation the valve is closed preventing air flow to the diseased area of the lung. The valve opens during exhalation to allow air to escape from the diseased area of the lung. When used to treat persistent air leak from the lung into the pleural space, the endobronchial valve theoretically permits less air flow across the diseased portion of the lung during inhalation aiding in air leak closure. The valve may be placed, and subsequently removed, by bronchoscopy.

Endobronchial valves have also been investigated for use in severe emphysematous COPD. In emphysematous COPD peripheral lung tissue may form bullae. These diseased portions of the lung ventilate poorly, cause air trapping, and hyperinflate, compressing relatively normal lung tissue. They also may rupture, causing a pneumothorax. Use of an endobronchial valve is thought to prevent hyperinflation of these bullae.

Consideration for the use of endobronchial valves in COPD is based on the improvement observed in patients who have undergone lung volume reduction surgery (LVRS). LVRS involves excision of
Endobronchial Valves

Peripheral emphysematous lung tissue, generally from the upper lobes. The precise mechanism of clinical improvement for patients undergoing lung volume reduction has not been firmly established. However, it is believed that elastic recoil and diaphragmatic function are improved by reducing the volume of diseased lung. The procedure is designed to relieve dyspnea and improve functional lung capacity and quality of life; it is not curative. Endobronchial valves have been investigated as a nonsurgical alternative to LVRS.

Regulatory Status

In October 2008, the “IBV® Valve System” (Spiration, Inc, Redmond, WA) was approved by the FDA under the Humanitarian Device Exemption (HDE) for use in controlling prolonged air leaks of the lung or significant air leaks that are likely to become prolonged air leaks following lobectomy, segmentectomy, or lung volume reduction surgery (LVRS). An air leak present on postoperative day 7 is considered prolonged unless present only during forced exhalation or cough. An air leak present on day 5 should be considered for treatment if it is: 1) continuous, 2) present during normal inhalation phase of inspiration, or 3) present upon normal expiration and accompanied by subcutaneous emphysema or respiratory compromise. IBV Valve System use is limited to 6 weeks per prolonged air leak.

In December 2008, the “Zephyr Endobronchial Valve” (formerly Emphasys, now Pulmonx, Redwood City, CA) was considered by the Anesthesiology and Respiratory Therapy Device Panel for use as a permanent implant intended to improve forced air expiratory volume in one second (FEV1) and 6-minute walk test distance in patients with severe, heterogeneous emphysema who have received optimal medical management. The panel declined to recommend the device for FDA approval. As of May 2017, the Zephyr Endobronchial Valve has not been cleared by the FDA.

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy

Endobronchial valves are considered investigational for all applications. BCBSNC does not provide coverage for investigational services or procedures.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Endobronchial Valves are covered

Not applicable.

When Endobronchial Valves are not covered

Endobronchial valves are considered investigational in all situations including, but not limited to:

- Treatment of prolonged air leaks
- Treatment for patients with chronic obstructive pulmonary disease (COPD) or emphysema
Endobronchial Valves

Policy Guidelines

Endobronchial valves are synthetic devices that are deployed with bronchoscopy into ventilatory airways of the lung for the purpose of controlling airflow. They have been investigated for use in patients who have prolonged broncho-pleural air leaks, as well as an alternative to lung volume reduction surgery (LVRS) in patients with lobar hyperinflation from severe emphysema.

For individuals who have pulmonary air leaks who receive endobronchial valves, the evidence includes case series. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, and treatment-related morbidity. The only available data on endobronchial valves for treating persistent air leaks are uncontrolled trials with small numbers of heterogeneous patients. Data on the Spiration™ endobronchial valve device (the only device approved by the U.S. Food and Drug Administration [FDA]) are particularly limited. These valves were successfully placed in 7 patients in 1 case series and in 9 patients in another series. These case series do not provide any evidence on comparisons with alternatives. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have severe or advanced emphysema who receive endobronchial valves, the evidence includes seven randomized controlled trials (RCTs) and a systematic review of these trials. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, and treatment-related morbidity. Of the seven RCTs, five did not use FDA-approved valves. For the FDA-approved Spiration® IBV, there was no improvement in quality of life or exercise capacity in the combined results. Although some outcomes of the larger trials were statistically significant for bronchial valve treatment, the magnitude of the difference was generally of uncertain clinical significance. Moreover, the numerous adverse events experienced by patients who received endobronchial valves in these trials raise concerns about treatment safety. Overall, it is not possible to determine whether there is a clinically meaningful benefit. The evidence is insufficient to determine the effects of the technology on health outcomes.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 31647, 31648, 31649, 31651

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources


Senior Medical Director Review 11/2010

Endobronchial Valves


Specialty Matched Consultant Advisory Panel review 3/2012


Specialty Matched Consultant Advisory Panel review 3/2015


Specialty Matched Consultant Advisory Panel review 3/2017


Specialty Matched Consultant Advisory Panel review 3/2018


**Policy Implementation/Update Information**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/21/10</td>
<td>New policy issued. Endobronchial valves are considered investigational as a treatment of prolonged air leaks. Endobronchial valves are considered investigational as a treatment for patients with COPD or emphysema. Notice given 12/21/2010 with effective date 3/29/11. (lpr)</td>
</tr>
<tr>
<td>4/17/12</td>
<td>Specialty Matched Consultant Advisory Panel review 3/21/2012. References and Policy Guidelines updated. No change to policy statement. (lpr)</td>
</tr>
<tr>
<td>12/28/12</td>
<td>Added CPT codes 31647, 31648, 31649, 31651 to the Billing/Coding section for effective date 1/1/2013. Deleted CPT codes 0250T, 0251T, 0252T. (lpr)</td>
</tr>
</tbody>
</table>
Endobronchial Valves

4/16/13 Updated Policy Guidelines section. Specialty Matched Consultant Advisory Panel review meeting 3/20/13. References added. No change to policy statement. (lpr)

5/13/14 Specialty matched consultant advisory panel review meeting 4/30/2014. No change to policy statement. Reference updated. (lpr)

4/28/15 Updated “Policy Guidelines.” Reference added. Specialty matched consultant advisory panel review 3/25/2015. No change to policy statement. (lpr)

4/29/16 Updated Policy Guidelines and Description sections. Revised the When Not Covered statement to indicate “all” situations to clarify intent. No change to policy statement or intent. Specialty Matched Consultant Advisory Panel review 3/30/2016. (lpr)

7/26/16 Policy Guidelines updated. Reference added. No change to policy statement. (lpr)


7/28/17 Updated Policy Guidelines section. Reference added. No change to policy statement. (lpr)

4/13/18 Specialty Matched Consultant Advisory Panel review 3/28/2018. Reference added. No change to policy statement. (lpr)

7/27/18 Reference added. (lpr)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.